Poly Lactic-co-Glycolic Acid (PLGA)

Global Poly Lactic-co-Glycolic Acid (PLGA) Market to Reach US$349.2 Million by 2030

The global market for Poly Lactic-co-Glycolic Acid (PLGA) estimated at US$136.9 Million in the year 2024, is expected to reach US$349.2 Million by 2030, growing at a CAGR of 16.9% over the analysis period 2024-2030. High Lactic Acid Grade, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$255.7 Million by the end of the analysis period. Growth in the High Glycolic Acid Grade segment is estimated at 13.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$37.3 Million While China is Forecast to Grow at 22.5% CAGR

The Poly Lactic-co-Glycolic Acid (PLGA) market in the U.S. is estimated at US$37.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$77.8 Million by the year 2030 trailing a CAGR of 22.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.4% and 15.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Global Poly (Lactic-co-Glycolic Acid) (PLGA) Market – Key Trends & Drivers Summarized

Why Is PLGA Gaining Importance in Biomedical and Pharmaceutical Applications?

Poly (Lactic-co-Glycolic Acid) (PLGA) is a biodegradable and biocompatible polymer widely used in drug delivery systems, medical implants, tissue engineering, and regenerative medicine. Its ability to degrade into non-toxic byproducts (lactic acid and glycolic acid) makes it an ideal material for controlled drug release, absorbable sutures, orthopedic fixation devices, and nano/microparticle-based therapeutics.

The rising demand for biodegradable polymers in healthcare is a key driver for PLGA’s adoption. The global burden of chronic diseases, increasing need for targeted drug delivery, and advancements in tissue regeneration have significantly boosted PLGA usage in pharmaceutical and biomedical industries. Regulatory approvals from the U.S. FDA, European Medicines Agency (EMA), and other health agencies have further solidified its role in next-generation medical treatments.

Additionally, PLGA is highly tunable, allowing scientists to modify its degradation rate, mechanical properties, and drug-release kinetics by adjusting the ratio of lactic acid (LA) to glycolic acid (GA). This flexibility has led to widespread applications in nanoparticles, scaffold engineering, biosensors, and bioresorbable implants.

How Are Innovations in PLGA Technology Enhancing Its Market Potential?

The PLGA market is evolving rapidly with advancements in nanotechnology, personalized medicine, and 3D-printed biomedical materials.

One of the most significant innovations is PLGA-based nanoparticles and microparticles for controlled drug delivery. Nanoparticle-based drug carriers improve drug stability, solubility, and bioavailability, allowing for sustained and localized drug release. PLGA nanoparticles are widely used in oncology, gene therapy, vaccine delivery, and neurodegenerative disease treatments, enabling targeted delivery with minimal side effects.

Personalized medicine and gene therapy advancements are also driving demand for PLGA in next-generation drug delivery systems. Scientists are engineering PLGA-based nanocarriers for mRNA, CRISPR-based gene editing, and personalized cancer treatments, offering precision medicine solutions. The success of mRNA-based vaccines (such as COVID-19 vaccines) has accelerated research into PLGA-based lipid nanoparticle (LNP) alternatives for future vaccine formulations.

Additionally, 3D-printed PLGA scaffolds are transforming tissue engineering and regenerative medicine. PLGA’s biodegradable and bioresorbable properties make it ideal for bone, cartilage, and soft tissue regeneration. 3D-printed PLGA biomaterials are now used in personalized implants, orthopedic grafts, and bioprinting applications, enabling customized medical solutions for patients.

The integration of PLGA with bioactive molecules (such as growth factors, peptides, and proteins) is further expanding its role in wound healing, dental applications, and nerve regeneration. Scientists are developing PLGA-based hydrogels, nanofibers, and composite biomaterials for advanced wound dressings and surgical applications, improving patient recovery outcomes.

Why Is Demand for PLGA Growing Across Healthcare and Biomedical Sectors?

The increasing use of PLGA across pharmaceutical, medical device, and biotechnology industries is driving market expansion. Key sectors benefiting from PLGA’s properties include:

• Pharmaceutical Drug Delivery: PLGA is extensively used in long-acting injectable drugs, microsphere-based formulations, and targeted nanoparticle therapeutics. PLGA-based drug delivery systems improve therapeutic efficacy, reduce dosing frequency, and enhance patient compliance, making them ideal for oncology, diabetes, cardiovascular diseases, and neurodegenerative disorders.
• Medical Implants & Sutures: The absorbable sutures, orthopedic pins, screws, and fixation devices market relies heavily on PLGA due to its biodegradability and biocompatibility. PLGA-based implants eliminate the need for surgical removal, reducing patient discomfort and post-operative complications.
• Tissue Engineering & Regenerative Medicine: PLGA scaffolds are being used for bone regeneration, cartilage repair, and soft tissue engineering. The development of PLGA-based stem cell delivery platforms has further expanded its applications in wound healing, vascular grafts, and nerve regeneration.
• Biodegradable Medical Devices: PLGA is being used in stent coatings, biosensors, and nanofiber-based wound dressings. The demand for biodegradable medical devices and implants is growing as hospitals and surgeons seek minimally invasive and patient-friendly solutions.
• Vaccine & Gene Therapy Development: PLGA nanoparticles are increasingly utilized in mRNA vaccine stabilization, DNA delivery, and CRISPR gene-editing platforms. Research into PLGA-based adjuvants and immunotherapies is expected to accelerate with the global rise in infectious disease preparedness.

What Factors Are Driving the Growth of the PLGA Market?

The growth in the PLGA market is driven by technological advancements, increasing demand for biodegradable medical solutions, and expanding applications in pharmaceuticals and regenerative medicine.

• Rising Demand for Controlled Drug Delivery: The shift from conventional drug formulations to long-acting injectables and targeted nanoparticle therapeutics has significantly increased PLGA usage in drug delivery applications.
• Advancements in Biodegradable & Bioresorbable Medical Devices: The rising adoption of bioabsorbable sutures, stents, and implants is driving demand for PLGA-based medical devices. As hospitals and surgical centers prioritize patient-friendly solutions, PLGA’s role in post-operative healing and implantable drug-eluting devices is expanding.
• Increasing Focus on Regenerative Medicine: The growth of tissue engineering and stem cell therapy research has positioned PLGA as a leading biomaterial for 3D-printed scaffolds, artificial organ regeneration, and personalized medicine applications.
• Government & Regulatory Support for Biodegradable Polymers: Regulatory agencies such as the FDA and EMA are promoting biodegradable and bioresorbable materials for medical use, leading to increased investment in PLGA-based biopolymers.
• Growing Investments in Vaccine & Nanomedicine Research: The success of mRNA vaccine platforms and targeted nanoparticle drug delivery has accelerated R&D in PLGA-based nanocarriers for next-generation vaccines, immunotherapies, and antiviral treatments.
• Sustainability & Biodegradability Initiatives: The global shift toward eco-friendly medical solutions is driving interest in biodegradable polymers for medical waste reduction, positioning PLGA as a sustainable alternative to petroleum-based medical plastics.

With ongoing innovations in nanomedicine, 3D bioprinting, and bioengineered implants, the PLGA market is set for rapid expansion. As healthcare providers, pharmaceutical companies, and biotech firms prioritize biodegradable and patient-friendly materials, PLGA will remain a key player in the future of drug delivery, regenerative medicine, and advanced medical device development.

 

SCOPE OF STUDY:

The report analyzes the Poly Lactic-co-Glycolic Acid (PLGA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Composition (High Lactic Acid Grade, High Glycolic Acid Grade); Processibility (Extrusion, Injection Molding, Other Processibilities); Application (Medical Application, Non-Medical Application); End-Use (Healthcare End-Use, Biotech Firms End-Use, Medical Institutions End-Use, Packaging End-Use, Textile End-Use, Agriculture End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Akina, Inc.
• Ashland Inc.
• Bezwada Biomedical, LLC
• BMG Incorporated
• CD Bioparticles
• Corbion N.V.
• Creative PEGWorks
• Evonik Industries AG
• Green Polymer Corporation
• Jinan Daigang Biomaterial Co., Ltd.
• Kureha Corporation
• LACTEL Absorbable Polymers (Durect Corporation)
• Merck KGaA
• Mitsui Chemicals, Inc.
• Nomisma Healthcare Pvt. Ltd.
• Polysciences, Inc.
• SEQENS
• Shandong Keyuan Pharmaceutical Co., Ltd.
• Sigma-Aldrich Corporation
• Wego Chemical Group

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.